The growing awareness of sarcopenia and its detrimental effects on health is a significant development in the field of healthcare and aging. There has been a significant increase in research and publications related to sarcopenia. Scientific studies, medical journals, and publications have provided healthcare professionals with valuable information about the condition's prevalence, diagnosis, and consequences. Medical schools and training programs have incorporated sarcopenia into their curricula. This ensures that healthcare professionals, including doctors, nurses, and physical therapists, receive education about sarcopenia, its risk factors, and management strategies.
Various advocacy groups and organizations have been actively promoting awareness about sarcopenia. These groups often collaborate with healthcare professionals to educate the public about the conditions risks and the importance of early diagnosis and intervention. Sarcopenia has received increased coverage in mainstream media, including articles, news reports, and documentaries. This exposure has helped raise awareness among the general public.
Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-sarcopenia-treatment-market
Data Bridge Market Research analyses that the Sarcopenia Treatment Market is expected to grow with a CAGR of 5.9% in the forecast period from 2023 to 2030, and is expected to reach USD 861,882.42 thousand by 2030.
Key Findings of the Study
Growing Awareness of Sarcopenia and its Detrimental Effects on Health
The growing awareness of sarcopenia and its detrimental effects on health is a significant development in the field of healthcare and aging. There has been a significant increase in research and publications related to sarcopenia. Scientific studies, medical journals, and publications have provided healthcare professionals with valuable information about the condition's prevalence, diagnosis, and consequences. Medical schools and training programs have incorporated sarcopenia into their curricula. This ensures that healthcare professionals, including doctors, nurses, and physical therapists, receive education about sarcopenia, its risk factors, and management strategies.
Various advocacy groups and organizations have been actively promoting awareness about sarcopenia. These groups often collaborate with healthcare professionals to educate the public about the conditions risks and the importance of early diagnosis and intervention. Sarcopenia has received increased coverage in mainstream media, including articles, news reports, and documentaries. This exposure has helped raise awareness among the general public.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
Japan, Australia, India, China, South Korea, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Abbott (U.S.), Nestlé Health Science (A subsidary of Nestlé S.A.) (Switzerland), Novartis AG (Switzerland), Sanofi (France), Haleon Group of Companies.(England), BASF SE (Germany), DSM (Netherlands), Fermenta Biotech Limited (India), AstaReal Co., Ltd.(Japan), Metagenics (U.S.), Wellona Pharma (India), The Vitamin Company India (India), Healing Pharma India Pvt. Ltd. (India), ONCOCROSS CO.,LTD (South Korea), Dystrogen Therapeutics Corp (U.S.), OPKO Health, Inc. (U.S.), ImmunoForge Inc (South Korea), Regeneron Pharmaceuticals Inc. (U.S.), Biophytis (France), ARMGO Pharma, Inc. (U.S.), Rejuvenate Biomed NV. (Belgium) and among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Asia-Pacific sarcopenia treatment market is segmented into seven notable segments such as treatment type, type, stages, route of administration, gender, end user, and distribution channel.
- On the basis of treatment type, the market is segmented into medications, vitamin/dietary supplements, and others.
In 2023, the vitamin/dietary supplements segment is expected to dominate the Asia-Pacific Sarcopenia Treatment Market
In 2023, the vitamin/dietary supplements segment is expected to dominate the market with a market share of 49.68% due to its increasing demand among the population.
- On the basis of type, the market is segmented into primary sarcopenia and secondary sarcopenia.
In 2023, the primary sarcopenia segment is expected to dominate the Asia-Pacific sarcopenia treatment market
In 2023, primary sarcopenia segment is expected to dominate the market with a market share of 60.09% due to its rising prevalence among population.
- On the basis of stages, the market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia. In 2023, pre-sarcopenia segment is expected to dominate the market with a market share of 44.30%.
- On the basis of route of administration, the market is segmented into oral, injectable, and others. In 2023, oral segment is expected to dominate the market with a market share of 57.64%.
- On the basis of gender, the market is segmented into male and female. In 2023, male segment is expected to dominate the market with a market share of 62.82%.
- On the basis of end user, the market is segmented into hospitals, specialty clinics, home healthcare, and others. In 2023, hospitals segment is expected to dominate the market with a market share of 54.72%.
- On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2023, direct tender segment is expected to dominate the market with a market share of 69.12%.
Major Players
Data Bridge Market Research analyzes Abbott (U.S.), Nestlé Health Science (A subsidiary of Nestlé S.A.) (Switzerland), Novartis AG (Switzerland), Sanofi (France), and BASF SE (Germany) as the market players in Asia-Pacific sarcopenia treatment market.
Market Development
- In August 2023, Haleon, Asia-Pacific leader in consumer health, and Direct Relief, announced that a humanitarian aid organization, have agreed to a multi-year commitment to expand access to everyday health for underserved communities while boosting emergency response and preparedness efforts around the world. This will increase the company brand image.
- In June 2023, Sanofi announced that its consumer healthcare business unit had launched a new open innovation portal, allowing the wider supply chain community to submit their creative, disruptive, and game-changing solutions to meet the challenges of an ever-evolving consumer healthcare landscape. This helps the organisation in developing more revenue.
- In February 2023, Nestlé Health Science announced that they entered into a research collaboration with EraCal Therapeutics, to identify novel nutraceuticals relevant to controlling food intake. This increased the company product portfolio and overall revenue.
- In November 2022, Abbott announced that it has been awarded by the Consumer Technology Association (CTA) with three CES 2023 innovation awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.
- In July 2022, AstaReal Co., Ltd. announced that AstaReal Astaxanthin was awarded cognitive function ingredient of the year 2022. This helps the organization in developing brand image.
Regional Analysis
Geographically, the countries covered in the Asia-Pacific sarcopenia treatment market report are Japan, Australia, India, China, South Korea, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, and Rest of Asia-Pacific.
As per Data Bridge Market Research analysis:
Japan is the dominating and fastest growing country in Asia-Pacific sarcopenia treatment market
Japan is expected to dominate and fastest the Asia-Pacific sarcopenia treatment market owing to the higher level of investments by various manufacturers and increasing demand for pharmaceutical products manufacturing in the region.
For more detailed information about the Asia-Pacific sarcopenia treatment market report, click here – https://www.databridgemarketresearch.com/reports/asia-pacific-sarcopenia-treatment-market
